Welcome on board!
Pharnext is an advanced clinical-stage biopharmaceutical company committed to developing novel innovative therapeutics for orphan and common diseases with high unmet medical need.
Our proprietary R&D platform, PLEOTHERAPY™, systematically leverages genomic big data and AI to identify synergistic combinations of approved drugs or NCEs to generate new therapeutics with the potential to safely and effectively target and treat diseases.
Date
Number of shares composing the share capital
Theoretical number of voting rights
March 31, 2021
21,923,469*
26,208,688
*Including 2,595,000 new shares issued from the equity line financing with Kepler Cheuvreux announced on November 19th 2019..
Stock Market
Euronext Growth Paris
Mnemo
ALPHA
Bloomberg
ALPHA/FR – Reuters: ALPHA.PA
ISIN Code
FR0011191287
Closing date
31 December
First day of trading
18 July 2016
Number of shares
21,923,469
Indices
EnterNext© PEA-PME 150,
Euronext Growth All-Share, Next Biotech, PEA
Liquidity contract
Kepler Cheuvreux
Eligible to PEA-PME (French fiscal advantage)
Share price
The analysts listed on the right follow PHARNEXT. Any opinions, estimates or forecasts made by these analysts regarding PHARNEXT are individual and do not represent opinions, forecasts or predictions of PHARNEXT's management. PHARNEXT does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.
Kepler Cheuvreux : Damien Choplain - email
Gilbert Dupont : Guillaume Cuvillier - email
Edison Group : Nathaniel Calloway - email
Initiation of coverage report*
R&D Day Event report*
Report on PREMIER trial initiation*
Report on the Open-Label Phase III Extension Study of PXT3003*
* These hyperlinks to a third party website are provided for information only and do not constitute an endorsement of any content provided therein.
Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)
Pharnext Reports Financial Results for Year-End 2020
Pharnext Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Clinical Development Program of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)
Pharnext Announces Financing of €11 Million Through a Capital Raise Subscribed by Existing Shareholders and a Convertible Bonds Issued to European Investors; European Investors Also Provide Indication of Interest for an Additional Amount of up to €25 Million in Convertible Bonds
Pharnext Provides an Update on its Pivotal Clinical Development Program in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)
Corporate presentation
Pharnext Corporate Presentation
Presentation of the PLEO-CMT-FU extension study update
Recording of the webcast presentation of the PLEO-CMT-FU extension study update
Presentation of the R&D Day Event
Highlights of the R&D Day Event
General meeting
General meeting
General meeting
General meeting
Letter to shareholders
Letter to Shareholders
Letter to Shareholders n°4
Letter to Shareholders n°3
Letter to Shareholders n°2
Letter to Shareholders n°1
Regulated Information
Auditors’ report on Financial year 2020
Auditors’ report on IFRS Financial statement 2020
Management report 2020 from the board of directors for the 2020 financial year (French only)
2020 Annual Financial results IFRS
French Gaap Financial Statement 2020
Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison
Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison